This editorial refers to 'Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation' † , by P. Kirchhof et al., on page 2942.
Over the past two decades, catheter ablation of atrial fibrillation (AF) has become increasingly safe and effective. Most complications of AF ablation are due to haemorrhage, thrombosis, or both. Patients with AF carry a baseline risk of thrombo-embolism that is increased during the peri-procedural period. The increased thrombotic risk is due to intraprocedural introduction of foreign bodies into the left atrium, char formation on the ablation catheter tip, thrombus formation within the lumens of long sheaths, and the potential for thrombus formation on the ablated atrial endocardium. As such, optimal management of peri-procedural anticoagulation has been a key focus for improving the safety of AF ablation. Initially, AF ablations were performed using interrupted warfarin with post-procedure bridging with heparin until data emerged that uninterrupted warfarin reduced the risk of both haemorrhage and thrombo-embolism. 1 Since the introduction of the non-vitamin K 4 This trial assessed whether uninterrupted apixaban was noninferior to uninterrupted warfarin at the time of AF ablation. The study randomized 674 patients to uninterrupted vitamin K antagonist (VKA) or uninterrupted apixaban. The primary endpoint was a composite of all-cause death, stroke, or major bleeding, with major bleeding defined by a Bleeding Academic Research Consortium (BARC) category of > _2, which includes clinically 'actionable' bleeding, over 3 months after the index procedure. Bleeding was also adjudicated according to the ISTH and Thrombolysis in Myocardial Infarction (TIMI) criteria. An important aspect of AXAFA-AFNET 5 was the assessment of changes in cognitive function and, in a substudy, assessment of acute subclinical cerebral infarction as manifest by brain lesions on post-procedure magnetic resonance imaging (MRI; 3-48 h after ablation). A total of 22/318 (6.9%) patients randomized to apixaban and 23/315 (7.3%) patients randomized to VKA reached the primary endpoint. While the trial met its criteria of excluding a 7.5% absolute risk increase with 95% confidence, the observed confidence interval included as much as a 40% relative increase in risk. Moreover, while the stroke rate was very low, there were two strokes in the apixaban and none in the VKA arm. The rate of ISTH major bleeding was 3.1% in the apixaban and 4.4% in the warfarin arm.
Consistent with most 5 but not all 6 prior reports, acute brain lesions occurred in 1 in 4 patients in the MRI substudy. The rates of these lesions did not differ by treatment group. Importantly, cognitive
The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology. The results from AXAFA-AFNET 5 are important as they provide evidence that uninterrupted apixaban is a reasonable alternative to uninterrupted VKA at the time of AF ablation. However, the modest number of events in the trial, with corresponding wide confidence intervals, makes it important to interpret the results in the context of the other trials. The primary finding of non-inferiority is consistent with the results of VENTURE-AF and RE-CIRCUIT. Notably, the rates of ISTH major bleeding in the VKA arm of AXAFA-AFNET 5 were higher than in VENTURE-AF (0.8%), but somewhat lower (4.4%) than in RE-CIRCUIT (6.9%) despite AXAFA-AFNET 5 having a longer follow-up and slightly higher co-morbidity burden (assessed by CHA 2 DS 2 -VASc score). Another important difference was that VKA management was better than in RE-CIRCUIT (time in therapeutic range of 84% vs. 66%).
The most striking finding of AXAFA-AFNET 5 was the very common (1 in 4 patients) occurrence of brain lesions detected by MRI, irrespective of treatment group. There is uncertainty as to the clinical significance of these lesions when they occur without symptoms or change in cognitive function. However, they do represent acute cerebral infarction based on imaging characteristics, and thus they are potentially important. While the focus for safety has been on bleeding, the occurrence of subclinical cerebral infarction is much more common than major bleeding (Take home figure) . It would seem reasonable to include this outcome as an important one in future trials assessing safety of ablation procedures. 7 Understanding and minimizing 'covert' central nervous system infarctions is important in other procedures as well, such as transcatheter aortic valve replacement. 7 While minimizing subclinical cerebral infarction is a logical goal, it is possible that this acute complication may be outweighed by longer term benefits of sinus rhythm. It should also be noted that although differences in MRI scanners and protocols can change the sensitivity for detecting these lesions, 5 making across-study comparisons difficult, the rates of silent cerebral infarctions in the AXAFA-AFNET 5 trial are within the range of most previous reports. It is somewhat disappointing that apixaban, which affords more reliable and consistent anticoagulation, did not appear to have any measurable impact on the incidence of these lesions. Although our understanding of what causes these silent lesions is incomplete, the existing evidence does suggest that optimal peri-procedural anticoagulation may reduce their occurrence. A study by Di Biase et al. identified a subtherapeutic international normalized ratio (INR) on the day of the AF ablation and two consecutive intraprocedural activated clotting times (ACTs) <300 s as risk factors for silent brain lesions. 8 Although this study did not include patients on NOAC therapy, it is reasonable to conclude that the more predictable anticoagulation effect of NOACs may imply a potential role for minimizing risk for silent cerebral infarctions. It is worth considering the potential implications of the fact that patients on NOACs often require higher doses of heparin to achieve a therapeutic intraprocedural ACT and that subtherapeutic ACTs are somewhat more common. It is not exactly clear what causes this phenomenon, but many feel it is related to actual differences in coagulation rather than an interaction between NOACs and the ACT assay itself. 9 In AXAFA-AFNET 5, patients randomized to apixaban had a lower median ACT (310 vs. 348) and were more likely to have at least one ACT below 300 s (76.9% vs. 48.9%) and 250 s (41.1% vs. 26.7%). Future investigation should determine whether subtherapeutic ACTs are associated with a similar risk of silent cerebral infarctions in patients treated with NOACs (similar to VKAs) and whether more aggressive heparin dosing may reduce the incidence of these lesions. Additional research is also required to better understand the clinical significance and persistence of these lesions.
In conclusion, the AXAFA-AFNET 5 investigators have demonstrated that it is reasonable to perform AF ablation on uninterrupted apixaban, adding to the evidence that it appears safe to perform AF ablation on uninterrupted NOAC therapy. Additionally, the investigators highlight an important area for further investigation in the field of AF ablation: the critical need to better understand the significance of and how to minimize subclinical cerebral infarction.
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